BACKGROUND - For men with advanced castration-resistant prostate cancer (CRPC), several treatment options are available, including androgen receptor (AR) pathway inhibitors (abiraterone acetate, enzalutamide), taxanes (docetaxel, cabazitaxel) and a radionuclide (radium-223).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
However, cross-resistance is a clinically relevant problem. Platinum compounds have been tested in a number of clinical trials in molecularly unselected prostate cancer patients. Advances in CRPC molecular profiling have shown that a significant proportion of patients harbour DNA repair defects, which may serve as predictive markers for sensitivity to platinum agents.
OBJECTIVE - To systematically identify and analyse clinical trials that have evaluated platinum agents in advanced prostate cancer patients.
METHODS - PubMed was searched to identify published clinical trials of platinum agents in advanced prostate cancer. The PRIMSA statement was followed for the systematic review process. Identified trials are analysed for study design, statistical plan, assessments of antitumour activity and the potential value of predictive biomarkers.
RESULTS - A total of 163 references were identified by the literature search and 72 publications that met the selection criteria were included in this review; of these 33 used carboplatin, 27 cisplatin, 6 satraplatin, 4 oxaliplatin and 2 other platinum compounds. Overall, antitumour activity varies in the range of 10-40% for objective response and 20-70% for PSA decline ≥50%. Response seemed highest for the combinations of carboplatin with taxanes or oxaliplatin with gemcitabine. The interpretation of the clinical data is limited by differences in response criteria used and patient populations studied.
CONCLUSIONS - Platinum compounds have moderate anti-tumour activity in molecularly unselected patients with advanced prostate cancer. Translational evidence of DNA repair deficiency should be leveraged in future studies to select prostate cancer patients most likely to benefit from platinum-based therapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2016 Apr 06 [Epub ahead of print]
S Hager, C J Ackermann, M Joerger, S Gillessen, A Omlin
Department of Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland., Department of Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland., Department of Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland., Department of Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland., Department of Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland.